Description
BGB-43395 is an investigational drug currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being evaluated in Phase 1 trials, which are early-stage studies designed to determine the safety and best way to give the drug. In colorectal cancer trials, BGB-43395 is being studied in patients whose tumors have a specific genetic change called a HER2 mutation. These trials are exploring BGB-43395 alone or in combination with other cancer therapies. As an investigational drug, it is not yet approved for use in colorectal cancer or any other condition.
Mechanism of Action
BGB-43395 is being investigated as a potential treatment for cancers with specific genetic changes. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is designed to target processes involved in cancer cell growth and survival. The trials are helping researchers understand how the drug interacts with cancer cells and whether it can effectively shrink tumors or slow their growth.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.